NIBEC Co., Ltd. (KOSDAQ:138610)
South Korea
· Delayed Price · Currency is KRW 29,800
+400 (1.36%)
At close: Mar 6, 2026
NIBEC Revenue
NIBEC had revenue of 5.17B KRW in the quarter ending September 30, 2025, a decrease of -10.67%. This brings the company's revenue in the last twelve months to 32.96B, up 44.48% year-over-year. In the year 2024, NIBEC had annual revenue of 24.55B with 56.33% growth.
Revenue (ttm)
32.96B
Revenue Growth
+44.48%
P/S Ratio
9.79
Revenue / Employee
343.34M
Employees
96
Market Cap
322.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24.55B | 8.85B | 56.33% |
| Dec 31, 2023 | 15.70B | -5.97B | -27.53% |
| Dec 31, 2022 | 21.67B | 8.05B | 59.04% |
| Dec 31, 2021 | 13.63B | 7.27B | 114.33% |
| Dec 31, 2020 | 6.36B | -2.93B | -31.55% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| curacle co.,ltd. | 1.14B |
| Y-Biologics | 3.61B |
| Bio Solution | 8.27B |
| ABION | 1.03B |
| S.Biomedics | 16.96B |
| Genome & Company | 25.95B |
| Prestige Biologics | 19.24B |
| TiumBio | 9.32B |